Results 91 to 100 of about 29,501 (185)

The ‘Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease’ (PATROL) study

BJU International, Volume 138, Issue 4, Page 600-606, October 2026.
Background Inherited (germline) pathogenic and likely pathogenic variants (gPVs) in key genes associated with increased risk of prostate cancer (PCa) now warrant more attentive PCa screening per National Comprehensive Cancer Network (NCCN) guidelines—e.g., BRCA2, HOXB13, ATM, BRCA1, MSH2, MSH6, CHEK2 and TP53.
Heather H. Cheng, Kara N. Maxwell, Keyan Salari, Matthew R. Cooperberg, Kristin Follmer, Joanne M. Jeter, Grace Jun, Daniel J. Lee, Hiten D. Patel, Edward M. Schaeffer, Alexandra O. Sokolova, Erika M. Wolff, Daniel W. Lin   +12 more
wiley   +1 more source

The Role of “Adult‐Onset” Cancer Predisposition Genes in Pediatric Cancer: A Comprehensive Review

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Current literature estimates that 10% of pediatric cancers are caused by pathogenic or likely pathogenic (P/LP) germline variants in cancer predisposition genes (CPGs). Variants in CPGs thought to increase cancer risk exclusively during adulthood are referred to as “adult‐onset” CPGs (aoCPGs).
Maria Rozo, Miriam A. Bornhorst, Angela J. Waanders, Sara Zarnegar‐Lumley, Ashwin Lakshman Koppayi, Lucy A. Godley   +5 more
wiley   +1 more source

Prevalence of MSI‐H/dMMR Colorectal Cancer in Japan: Data From the Clinical Study Group of the University of Osaka‐Colorectal Registry

Annals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1538-1545, September 2026.
Using a multicenter Japanese colorectal cancer cohort from 25 institutions, we analyzed 1464 patients across all disease stages and tumor locations to determine the prevalence and clinicopathological features of MSI‐H/dMMR colorectal cancer. MSI‐H/dMMR tumors accounted for 9.4% of cases overall, were present in 22% of right‐sided colon cancers, and ...
Yoshihiro Morimoto, Mamoru Uemura, Yoshinori Kagawa, Hidekazu Takahashi, Masayuki Hiraki, Yozo Suzuki, Shinichi Yoshioka, Mitsuyoshi Tei, Shu Okamura, Yukako Mokutani, Atsushi Naito, Shinji Tokuyama, Takamichi Komori, Akinobu Yasuyama, Genta Sawada, Yujiro Fujie, Shinya Yamashita, Naotsugu Haraguchi, Yusuke Matsuura, Chu Matsuda, Yoshinao Chinen, Tatsushi Shingai, Katsuki Danno, Nobuo Tanaka, Kazuya Sakata, Kohei Murata, Yuichiro Doki, Hidetoshi Eguchi   +27 more
wiley   +1 more source

The Molecular and Immunological Landscape in Nasopharyngeal Carcinoma (NPC) Differs by Somatostatin Receptor 2 (SSTR2) Expression

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Somatostatin receptor 2 is expressed in nasopharyngeal carcinoma (NPC). We report genomic and transcriptomic analysis results of 163 NPC cases, demonstrating that somatostatin receptor 2 (SSTR2) gene expression in EBV‐positive and in EBV‐negative NPC correlated with genomic alterations and an inflamed microenvironment.
Dara Bracken‐Clarke, Elisabetta Xue, Harris Krause, Tolulope Adeyelu, Mark G. Evans, Dilara Akbulut, Martha Quezado, Nishant Gandhi, Alex Farrell, Heloisa P. Soares, Emil Lou, Minh Phan, Rusha Patel, Ari M. Vanderwalde, Andrew Elliott, Conor E. Steuer, Nabil F. Saba, Daniel J. Lubin, Nyall R. London Jr, James L. Gulley, Charalampos S. Floudas   +20 more
wiley   +1 more source

Targeted Therapy, Immunotherapy, and Molecular Testing in Advanced Solid Tumors: A Medicare Analysis

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background and Purpose Biomarker testing and matched therapies are central to precision oncology, but their real‐world uptake and clinical impact among older adults with advanced solid tumors remain poorly characterized. This retrospective observational cohort study assessed biomarker testing and guideline‐concordant matched first‐line therapy
Onur Baser, Yijia Sun
wiley   +1 more source

Clinical Benefit of Pembrolizumab in Lynch Syndrome‐Associated Advanced Ovarian Cancer With Germline MSH6 Variant: A Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT This case highlights the importance of genetic evaluation during treatment in young patients with advanced ovarian cancer. Lynch syndrome caused by a germline MSH6 pathogenic variant was diagnosed during first‐line maintenance therapy, and pembrolizumab achieved a durable response in recurrent disease.
Tomomi Yokozawa, Sayako Nakagawa, Yukio Suzuki, Aya Tokinaga‐Uchiyama, Katsuyuki Konnai, Hiroto Narimatsu, Yukihiko Hiroshima, Haruya Saji   +7 more
wiley   +1 more source

Rare single‐nucleotide variants of MLH1 and MSH2 genes in patients with Lynch syndrome

Cancer Reports
Background Approximately 5% of colorectal cancers (CRCs) are hereditary. Lynch syndrome (LS), also known as hereditary nonpolyposis colorectal cancer (HNPCC), is the most common form of recognized hereditary CRC.
Seyed Mohsen Mirabdolhosseini, Mohammad Yaghoob Taleghani, Leili Rejali, Hossein Sadeghi, Nayeralsadat Fatemi, Mehdi Tavallaei, Amin Famil Meyari, Narges Saeidi, Pardis Ketabi Moghadam, Amir Sadeghi, Hamid Asadzadeh Aghdaei, Mohammad Reza Zali, Ehsan Nazemalhosseini Mojarad   +12 more
doaj   +1 more source

Sintilimab Combined With Albumin‐Bound Paclitaxel and SOX Regimen as Conversion Therapy for Unresectable Advanced Gastric Cancer Achieving Complete Remission: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT For carefully selected patients with unresectable advanced gastric cancer, immunochemotherapy combining PD‐1 inhibitor with albumin‐bound paclitaxel and S‐1/oxaliplatin may achieve deep remission and enable successful R0 resection. Our findings suggest that this multimodal conversion approach could be considered in selected cases with ...
Yufan Tang, Boquan Zhou, Bingbing Wen, Ke Yu, Jiajia Jia, Ying Sha, Jixiang Liu, Luyao Li, Ruifang Fan   +8 more
wiley   +1 more source

Characterizing Chromosomal Aberrations in Cells Deficient for Both ATM and MSH2 [PDF]

, 2019
Ataxia telangiectasia mutated (ATM) and mutS homologue 2 (MSH2) are important DNA repair proteins that participate in DNA repair pathways to maintain genomic integrity. Mice deficient for ATM and MSH2 mice are viable.
Inalman, Yeliz
core   +1 more source

Microsatellite Instability in Mouse Models of Colorectal Cancer

Canadian Journal of Gastroenterology and Hepatology, 2018
Microsatellite instability (MSI) is caused by DNA mismatch repair deficiency and is an important prognostic and predictive biomarker in colorectal cancer but relatively few studies have exploited mouse models in the study of its clinical utility ...
Nicola Currey, Joseph J. Daniel, Dessislava N. Mladenova, Jane E. Dahlstrom, Maija R. J. Kohonen-Corish   +4 more
doaj   +1 more source